Aimovig is a novel monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. CGRP is involved in vasodilation and sensory transmission, and is a validated target that is believed to play a key role in migraine headache. Aimovig targets the CGRP receptor; this mechanism differentiates it from other investigational anti-CGRP antibodies, which bind to the ligand. Aimovig is administered via subcutaneous injection once monthly.

If you have a Hayes login, click here to view the full report on the Knowledge Center.